000	00000nam 22000008i 4500
001	9.915979
003	CaOODSP
005	20221123103203
006	m     o  d f
007	cr cn|||||||||
008	221006e20220901onc     ob   f000 0 eng d
020	|a9780660457246|q(report)
020	|a9780660457253|q(summary)
040	|aCaOODSP|beng|erda|cCaOODSP
043	|an-cn---
086	1 |aHP5-142/1-2022E-1-PDF
086	1 |aHP5-142/2-2022E-1-PDF
245	00|aRecommendations on the use of bivalent Omicron-containing mRNA COVID-19 vaccines.
264	1|aOttawa, ON : |bPublic Health Agency of Canada = Agence de la santé publique du Canada, |cSeptember 1, 2022.
264	4|c©2022
300	|a1 online resource (27 pages) + |e1 summary (8 pages)
336	|atext|btxt|2rdacontent
337	|acomputer|bc|2rdamedia
338	|aonline resource|bcr|2rdacarrier
500	|aIssued also in French under title: Recommandations sur l'utilisation des vaccins à ARNm bivalents contre la COVID-19 contenant le variant Omicron.
500	|aAt head of title: An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI).
500	|a"Updated: October 7, 2022."
504	|aIncludes bibliographical references (pages 17-22).
520	|a"On June 29, 2022, NACI published interim guidance on planning considerations for a fall 2022 COVID-19 vaccine booster program in Canada. The statement outlined recommendations for booster doses in specific populations ahead of the uncertain trajectory of the COVID-19 pandemic in the coming months"--Background, page 3.
650	0|aCOVID-19 (Disease)|xVaccination|zCanada.
650	0|aCOVID-19 vaccines|zCanada.
710	2 |aPublic Health Agency of Canada, |eissuing body.
775	08|tRecommandations sur l'utilisation des vaccins à ARNm bivalents contre la COVID-19 contenant le variant Omicron.|w(CaOODSP)9.915980
795	|tRecommendations on the use of bivalent Omicron-containing mRNA COVID-19 vaccines.|w(CaOODSP)9.914912
856	40|qPDF|s1.41 MB|uhttps://publications.gc.ca/collections/collection_2022/aspc-phac/HP5-142-1-2022-1-eng.pdf|z(report)
856	40|qPDF|s1.23 MB|uhttps://publications.gc.ca/collections/collection_2022/aspc-phac/HP5-142-2-2022-1-eng.pdf|z(summary)